Peptidyl-prolyl cis-trans isomerase, microsomal Antibody

What is peptidyl-prolyl cis-trans isomerase and how does it affect antibody structure?

Peptidyl-prolyl cis-trans isomerases are enzymes that catalyze the interconversion of peptidylprolyl imide bonds in peptide and protein substrates. These enzymes facilitate the conversion between cis and trans conformations of proline residues, which can significantly impact protein folding and function. In antibodies, proline isomerization in complementarity-determining regions (CDRs) can alter structural conformations that directly influence antigen binding profiles. This isomerization represents a critical post-translational modification that can lead to conformational heterogeneity in antibody populations. The process can be particularly influential when proline residues are located within CDRs that directly contact antigens, potentially affecting binding affinity and specificity.

What are the major families of peptidyl-prolyl isomerases relevant to antibody research?

The peptidyl-prolyl isomerase superfamily includes three major unrelated families: cyclophilins, FK506-binding proteins (FKBPs), and parvulins. Though structurally distinct, these families catalyze the same fundamental reaction—the interconversion of peptidylprolyl imide bonds. Cyclophilins are targets of the immunosuppressant cyclosporin A (CsA), while FKBPs bind FK506. Both enzyme families have roles beyond isomerization, particularly in immune regulation. Parvulins, including the mitotic regulator Pin1, specifically recognize phosphorylated serine/threonine-proline motifs and are integral to cell cycle regulation. In antibody research, these enzymes are relevant because they may modulate antibody structure by catalyzing isomerization of proline residues in CDRs, potentially affecting antigen recognition and binding properties.

How does proline isomerization impact antibody analytical profiles?

Proline isomerization can significantly affect antibody analytical profiles, manifesting as anomalous behavior in chromatographic separations. For example, studies have documented antibodies exhibiting aberrant two-peak size-exclusion chromatography profiles resulting from proline isomerization in CDR regions. In one specific case involving a trispecific anti-HIV antibody, proline isomerization in the tyrosine-proline-proline (YPP) motif in the heavy chain CDR3 domain resulted in distinct chromatographic populations. This conformational heterogeneity was sensitive to pH conditions, suggesting environmental factors can influence the equilibrium between cis and trans conformers. These findings highlight the importance of considering proline isomerization when interpreting analytical data for antibody characterization and quality control assessments.

What analytical techniques can detect and quantify proline isomerization in antibodies?

Several complementary approaches can be employed to detect and quantify proline isomerization in antibodies:

• Size-exclusion chromatography (SEC): Can reveal heterogeneous populations resulting from different proline conformations in antibodies, often appearing as multiple peaks or peak shoulders.

• Structural analysis techniques:

  • X-ray crystallography: Provides high-resolution structural confirmation of cis versus trans proline conformations

  • NMR spectroscopy: Particularly 2D techniques that can detect and quantify the equilibrium between conformers in solution

• Molecular dynamics simulations: Computational approaches that model conformational transitions and energy landscapes of proline isomerization in specific antibody environments.

• Mass spectrometry with hydrogen/deuterium exchange: Can detect conformational differences resulting from proline isomerization.

• Circular dichroism spectroscopy: Useful for monitoring global structural changes resulting from proline isomerization.

The combination of these approaches, as demonstrated in studies of anti-HIV antibodies, allows researchers to establish causal relationships between proline isomerization and analytical or functional properties.

How can researchers modulate or control proline isomerization in antibody development?

Researchers can employ several strategies to modulate proline isomerization during antibody development:

• Structure-guided mutagenesis: Substituting proline residues or surrounding amino acids based on structural analysis can alter isomerization rates. For example, the histidine residue (H147) in proximity to the YPP motif in some antibodies has been shown to influence pH-dependent conformational equilibrium.

• Buffer optimization: pH conditions significantly affect proline isomerization equilibrium, particularly when histidine residues are adjacent to proline. Systematic buffer screening can identify conditions that favor desired conformers.

• Targeted use of PPIase enzymes: In vitro addition of specific PPIases can catalyze interconversion to desired conformations during antibody production or formulation.

• Temperature control: Isomerization rates are temperature-dependent, allowing thermal regimes to influence conformational distributions.

• Addition of stabilizing agents: Specific excipients can preferentially stabilize desired conformers in antibody formulations.

These approaches require careful characterization of the relationship between proline isomerization and the antibody's functional and analytical properties to ensure that interventions enhance rather than compromise desired characteristics.

What experimental approaches best characterize interactions between PPIases and antibodies?

To characterize interactions between PPIases and antibodies, researchers can employ these methodologies:

• Co-immunoprecipitation assays: These detect physical associations between PPIases and antibodies under native conditions. Specific protocols involve cell lysis in detergent-containing buffers (e.g., 0.2% NP-40 in TNE buffer), followed by precipitation with target-specific antibodies and immunoblotting for interacting partners.

• Surface plasmon resonance (SPR): Provides real-time binding kinetics and affinity measurements between purified PPIases and antibodies.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): Maps interaction interfaces by detecting regions protected from solvent exchange upon complex formation.

• Mutational analysis: Systematic mutation of potential contact residues (particularly S/TP motifs) helps identify specific interaction sites. For example, alanine scanning of serine/threonine-proline motifs has been used to map critical residues for Pin1 interactions.

• Stability assays: Assessment of antibody stability under stress conditions (e.g., freeze-thaw cycles, heat treatment) in the presence or absence of PPIases reveals functional consequences of the interaction.

These approaches collectively provide complementary information about the nature, specificity, and functional consequences of PPIase-antibody interactions.

How do PPIases affect viral infection processes relevant to antibody therapies?

PPIases play multiple critical roles in viral infection processes that have direct implications for antibody-based therapeutic strategies:

• Cyclophilin-HIV interactions: Human cyclophilins bind to the HIV-1 Gag polyprotein and play essential roles in viral infection, likely through facilitating uncoating of the virion. This interaction represents a potential target for therapeutic antibodies that could disrupt cyclophilin-dependent steps in the viral life cycle.

• Pin1-HBV interactions: The peptidyl-prolyl isomerase Pin1 interacts with hepatitis B virus (HBV) core particles through phosphorylated serine/threonine-proline motifs in the carboxyl-terminal domain. This interaction enhances core particle stability, promotes HBV DNA synthesis, and increases virion secretion. Importantly, inhibition of Pin1 through specific inhibitors or knockdown significantly reduces HBV replication.

• Viral protein stability: PPIases can modulate the folding and stability of viral proteins, affecting their recognition by host antibodies. Understanding these interactions can inform the design of antibodies targeting specific conformational epitopes.

• Immune modulation: The immunosuppressive actions of certain PPIases (through drug complexes like cyclophilin-CsA) can affect the broader immune response to viral infections, potentially impacting antibody production and efficacy.

These findings suggest that PPIases represent both potential therapeutic targets themselves and important factors to consider when developing antibody-based antiviral therapies.

What specific PPIase-viral protein interactions have been characterized at the molecular level?

Several PPIase-viral protein interactions have been characterized in detail, providing insights for antibody development:

• Pin1-HBV core particle interaction:

  • Interaction occurs specifically with assembled core particles, not with dimers or monomers

  • Critical motifs identified: 162TP, 164SP, and 172SP within the carboxyl-terminal domain

  • Pin1 binds both externally and internally to the core particle

  • Interaction is stronger with immature than mature core particles

  • Overexpression of Pin1 enhances HBV DNA synthesis and virion secretion without affecting HBV RNA levels

• Cyclophilin-HIV Gag interaction:

  • Human cyclophilin binds specifically to the HIV-1 Gag polyprotein

  • This interaction is essential for productive infection

  • The binding likely facilitates virion uncoating during early stages of infection

• S/TP motifs in viral proteins:

  • The amino-terminal domain 49SP motif contributes to core particle stability

  • The 128TP motif appears involved in core particle assembly

  • Mutation of these motifs (e.g., S49A) reduces stability during freeze-thaw cycles

  • T128A mutation results in impaired assembly

These characterized interactions provide molecular targets for antibody development, either to directly block PPIase-viral protein interactions or to stabilize specific conformations of viral proteins that may be more vulnerable to immune clearance.

How does pH influence proline isomerization in antibody complementarity-determining regions?

pH conditions significantly influence proline isomerization equilibrium in antibody CDRs through multiple mechanisms:

• Histidine-proline interactions: Histidine residues near proline can modulate isomerization rates in a pH-dependent manner due to their side chain pKa (~6-7). In the case of the trispecific anti-HIV antibody, a histidine residue (H147) in the light chain directly contacted the YPP motif in the heavy chain CDR3, influencing the conformational equilibrium between cis and trans states in a pH-dependent manner.

• Charge distribution: Changes in pH alter the charge distribution in the antibody microenvironment, affecting hydrogen bonding networks and electrostatic interactions that stabilize specific proline conformers.

• Protein dynamics: pH shifts can alter the global dynamics of the antibody structure, indirectly affecting the energy landscape for proline isomerization.

• Catalytic effects: The catalytic efficiency of endogenous PPIases that may associate with antibodies during expression can be pH-dependent, thereby influencing the conformational distribution.

These pH effects are particularly relevant for antibody manufacturing, storage, and in vivo performance across different physiological compartments where pH can vary substantially. Understanding these relationships enables rational pH optimization for desired conformational states.

What are the functional consequences of cis versus trans proline conformers in antibody-antigen interactions?

The cis versus trans conformation of proline residues in antibody CDRs can have profound consequences for antigen recognition and binding:

Understanding these functional consequences enables rational engineering of antibodies with optimized binding properties through strategic manipulation of proline conformations in CDRs.

What experimental conditions optimize detection of proline isomerization effects in antibodies?

Optimizing experimental conditions for detecting proline isomerization requires careful consideration of multiple parameters:

• Temperature control:

  • Lower temperatures (4-10°C) slow isomerization rates, potentially "trapping" conformers for analysis

  • Elevated temperatures accelerate equilibration, useful for studying kinetics

  • Temperature gradients can reveal thermodynamic parameters of isomerization

• pH optimization:

  • Studies should include pH ranges spanning 5.0-8.0 in 0.5 unit increments

  • Special attention to regions near histidine pKa (~6-7) when histidine residues are proximal to prolines

• Buffer composition:

  • Comparative analysis in different buffer systems (phosphate, Tris, HEPES) at identical pH values

  • Evaluation of ionic strength effects (50-300 mM range)

  • Inclusion/exclusion of divalent cations that may influence protein conformation

• Analytical separation conditions:

  • For SEC: varied flow rates, extended run times, and temperature-controlled columns

  • For chromatographic methods: testing multiple stationary phases with different selectivity profiles

• Sample preparation:

  • Fresh versus aged samples to capture time-dependent equilibration

  • Varied protein concentrations to detect concentration-dependent effects

• Stress conditions:

  • Repeated freeze-thaw cycles (as demonstrated effectively with HBV core particles)

  • Heat treatment followed by controlled cooling

These optimized conditions maximize the detection window for observing isomerization-related phenomena in antibody characterization and functional studies.

How can researchers effectively inhibit or enhance specific PPIases when studying their effects on antibodies?

Researchers can employ several strategies to modulate PPIase activity when investigating their effects on antibodies:

• Pharmacological inhibitors:

  • Cyclophilin inhibitors: Cyclosporin A and non-immunosuppressive derivatives

  • FKBP inhibitors: FK506, rapamycin and synthetic analogs

  • Parvulin/Pin1 inhibitors: Juglone, PiB (diethyl-1,3,6,8-tetrahydro-1,3,6,8-tetraoxobenzo[lmn] phenanthroline-2,7-dicarboxylate)

• Genetic approaches:

  • RNA interference: siRNA or shRNA targeting specific PPIases (demonstrated effectively with PIN1 knockdown in HBV studies)

  • CRISPR-Cas9 genome editing for complete knockout models

  • Overexpression systems utilizing mammalian expression vectors with strong promoters

• Protein-based modulators:

  • Recombinant PPIases for in vitro enhancement studies

  • Dominant-negative PPIase mutants

  • Engineered antibodies targeting specific PPIases

• Experimental controls:

  • Catalytically inactive PPIase mutants to distinguish between catalytic and scaffolding functions

  • Isozyme-specific approaches to target individual members of PPIase families

  • Dose-response studies to establish relationship between PPIase activity and observed effects

These approaches provide robust tools for dissecting the specific contributions of individual PPIases to antibody structure, stability, and function in both in vitro and cellular contexts.